Immunogenicity and Safety of Two Tetravalent (Measles, Mumps, Rubella, Varicella) Vaccines Coadministered with Hepatitis A and Pneumococcal Conjugate Vaccines to Children Twelve to Fourteen Months of Age

Pediatric Infectious Disease Journal

Volumn 31, Issue 8, 2012, Pages e133-e140

  Blatter, Mark M ^a   Klein, Nicola P ^a   Shepard, Julie S ^a   Leonardi, Michael ^a   Shapiro, Steven ^a   Schear, Martin ^a   Mufson, Maurice A ^a   Martin, Judith M ^a   Varman, Meera ^a   Grogg, Stanley ^a   London, Arnold ^a   Cambron, Pierre ^a   Douha, Martine ^a   Nicholson, Ouzama ^a   da Costa, Christopher ^a   Innis, Bruce L ^a  

^a Pediatric Alliance   (United States)

Author keywords

Measles; Mumps; Rubella; Varicella

Indexed keywords

ANTIBODY; ANTIPYRETIC AGENT; CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; HEPATITIS A VACCINE; PNEUMOCOCCUS VACCINE; PRIORIX TETRA; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; CHICKENPOX; CHILD; CONTROLLED STUDY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEBRILE CONVULSION; FEMALE; HEPATITIS A; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES; MULTICENTER STUDY; MUMPS; PAIN; PAROTID ENLARGEMENT; PHASE 2 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTOGENICITY; RUBELLA; SERODIAGNOSIS; SEROLOGY; SINGLE BLIND PROCEDURE; SKIN REDNESS; SWELLING; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHICKENPOX VACCINE; FEMALE; HEPATITIS A VACCINES; HERPES ZOSTER VACCINE; HUMANS; INFANT; MALE; MEASLES-MUMPS-RUBELLA VACCINE; PNEUMOCOCCAL VACCINES;

EID: 84863952921     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318259fc8a     Document Type: Article

References (33)

1. World Health Organization. Rubella vaccinesWHO position paper. Wkly Epidemiol Rec. 2000;75:161-172
2. World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec. 2001;76:346-355
3. World Health Organization. Measles vaccines. Wkly Epidemiol Rec. 2004;79:130-142
4. Zhou F, Reef S, Massoudi M, et al. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. J Infect Dis. 2004;189(suppl 1):S131-S145
5. Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1998;47(RR-8):1-57
6. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med. 1994;331:1397-1402
7. Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. J Infect Dis. 2004;189(suppl 1):S1-S3
8. World Health Organization. Varicella vaccines. WHO position paper. Wkly Epidemiol Rec. 1998;73:241-248
9. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002;347:1909-1915
10. Guris D, Jumaan AO, Mascola L, et al. Changing varicella epidemiology in active surveillance sites--United States, 1995-2005. J Infect Dis. 2008;19:S71-S75
11. Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics. 2008;122:e744-e751
12. Czajka H, Schuster V, Zepp F, et al. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine. 2009;27:6504-6511
13. Dietz VJ, Stevenson J, Zell ER, et al. Potential impact on vaccination coverage levels by administering vaccines simultaneously and reducing dropout rates. Arch Pediatr Adolesc Med. 1994;148:943-949
14. Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-7):1-23
15. American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine and antibiotic prophylaxis. Pediatrics. 2000;106:362-366
16. Wyeth Pharmaceuticals Inc. Pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein) July 2009. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=134. Accessed March 26, 2012.
17. GlaxoSmithKline. HAVRIX (hepatitis A vaccine). Highlights of prescribing information. HVX:35PI July 2011. Available at: http://us.gsk.com/products/assets/us_havrix.pdf. Accessed March 26, 2012.
18. Dodet M, Dessy F, Parent I, et al. Use of a neutralization assay as an alternative for assessing mumps immunization status. Program and Abstracts of the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases. May 3-5, 2006
19. Sato H, Albrecht P, Hicks JT, et al. Sensitive neutralization test for virus antibody. 1. Mumps antibody. Arch Virol. 1978;58:301-311
20. Poolman JT, Frasch CE, Käyhty H, et al. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol. 2010;17:134-142
21. Goh P, Lim FS, Han HH, et al. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection. 2007;35:326-333
22. Zepp F, Behre U, Kindler K, et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur J Pediatr. 2007;166:857-864
23. Vinals C, Gaulis S, Coche T. Using in silico transcriptomics to search for tumor-associated antigens for immunotherapy. Vaccine. 2001;19:2607-2614
24. Kuter BJ, Brown ML, Hartzel J, et al.Study Group for ProQuad. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccin. 2006;2:205-214
25. Lau YL, Vessey SJ, Chan IS, et al. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine. 2002;20:2942-2949
26. Spackova M, Wiese-Posselt M, Dehnert M, et al. Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine. 2010;28:686-691
27. Seward JF, Zhang JX, Maupin TJ, et al. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA. 2004;292:704-708
28. Marin M, Broder KR, Temte JL, et al.Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-3):1-12
29. Schuster V, Otto W, Maurer L, et al. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent ­measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J. 2008;27:724-730
30. Knuf M, Habermehl P, Zepp F, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006;25:12-18
31. Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126:e1-e8
32. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27:4656-4661
33. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics. 2011;128:630-632.